Skip to main navigation
Skip to search
Skip to main content
Experts@Minnesota Home
Home
Profiles
Research units
University Assets
Projects and Grants
Research output
Datasets
Press/Media
Activities
Fellowships, Honors, and Prizes
Impacts
Search by expertise, name or affiliation
Gene therapy for spinal muscular atrophy: Safety and early outcomes
Megan A. Waldrop
, Cassandra Karingada
, Mike A. Storey
, Brenna Powers
, Megan A. Iammarino
, Natalie F. Miller
, Lindsay N. Alfano
, Garey Noritz
, Ian Rossman
, Matthew Ginsberg
, Kathryn A. Mosher
, Eileen Broomall
,
Jessica Goldstein
, Nancy Bass
, Linda P. Lowes
, Chang Yong Tsao
, Jerry R. Mendell
, Anne M. Connolly
Research output
:
Contribution to journal
›
Article
›
peer-review
107
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Gene therapy for spinal muscular atrophy: Safety and early outcomes'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Spinal muscular Atrophy
100%
Gene Therapy
100%
Safety Outcomes
100%
Early Outcome
100%
Gene Transfer
75%
Onasemnogene Abeparvovec
75%
Child Age
50%
Prednisolone
50%
Glutamyl Transpeptidase
50%
Aspartate Aminotransferase
50%
SMN1 Gene
50%
Clinical Trials
25%
Ohio
25%
High Dose
25%
Outcome Assessment
25%
Platelets
25%
Replacement Therapy
25%
Gene-gene
25%
Older children
25%
Motor Function
25%
Clinical Symptoms
25%
Nineteen
25%
Young Subgroup
25%
Non-associated
25%
Autosomal Recessive
25%
Serum Transaminase
25%
First Week
25%
Alanine Aminotransferase
25%
Infant Death
25%
Gene Replacement Therapy
25%
Early Efficacy
25%
Management Replacement
25%
Transfer Management
25%
Alanine Aminotransferase Elevation
25%
Repeated Outcomes
25%
Medicine and Dentistry
Gene Therapy
100%
Spinal Muscular Atrophy
100%
Gene Transfer
75%
Onasemnogene Abeparvovec
75%
Gamma-Glutamyl Transpeptidase
50%
Aspartate Aminotransferase
50%
Alanine Aminotransferase
50%
Prednisolone
50%
Clinical Trial
25%
Outcome Assessment
25%
Platelet
25%
Drug Megadose
25%
Motor Performance
25%
Substitution Therapy
25%
Autosomal Recessive Inheritance
25%
Weakness
25%
Transaminase
25%
Serum Group
25%
Child Death
25%
Gene Replacement Therapy
25%
Clinical Symptom
25%
Pharmacology, Toxicology and Pharmaceutical Science
Spinal Muscular Atrophy
100%
Onasemnogene Abeparvovec
75%
Gene Delivery
75%
Replacement Therapy
50%
Gamma Glutamyltransferase
50%
Aspartate Aminotransferase
50%
Alanine Aminotransferase
50%
Prednisolone
50%
Clinical Trial
25%
Weakness
25%
Aminotransferase
25%
Child Death
25%